Building a Computational Model of Auditory Hallucinations

Prior treatment

• History of drug or alcohol dependence (except for caffeine and nicotine and mild/moderate cannabis dependence) in the 3 months before study start.

Other illness

• Impaired endocrine, cardiac, pulmonary, thyroid, haematological, hepatic, respiratory, neurological, immunological or renal function, or other major disease (e.g. cancer) deemed clinically significant at the time of the study.
• Recent history (i.e. in the last 12 months) of epilepsy or seizures.
• Contraindication to MRI, EEG or other study procedures (for example history of metal implants or metal pieces entering the body that cannot be removed safely, severe claustrophobia, allergy or skin sensitivity to EEG electrode gel).
• Any other condition or disability that would make participation in the study procedures not possible (for example severe vision or hearing impairment).
  • Healthy controls:
  • As above, and also:
  • 1\. No relevant family history of schizophrenia and psychosis (as judged relevant by a study researcher).

Lab values

• Clinically relevant abnormal history, or laboratory values at the pre-study screening assessment or participation in other research studies that could interfere with the objectives of the study or the safety of the participant, as deemed significant for a study researcher.

Other

• PWLEP:
• Homicidal ideation or intent, as judged by a researcher; suicidal ideation, with some intent to act, or suicidal behaviour, as judged by a researcher.
• Likelihood that the participant will not comply with the requirements of the protocol.

• PWLEP:
• Age 16-65 years.
• A score of at least 3 on the state section of the Auditory Perceptual Trait and State scale (APTS).
• If using an antipsychotic drug, participants must be on a stable dose of any medication during the baseline measures.
• Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.
• Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.
• Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.
  • Healthy controls:
• Age 16-65 years.
• Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.
• Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.
• Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.